Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Alamar Biosciences, Inc. (ALMR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$26.91-1.75%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ALMR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Narrowing loss per share | A supporting condition in Alamar Biosciences, Inc.'s published investment case. The stated target is <= -0.21 EPS. | Intact | EPS loss exceeds -0.21 next quarter | Diluted EPS: $-0.19 per share FY2026-Q3; GAAP. Published target: <= -0.21 EPS. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Nov 4, 2026-0.19 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ALMR is a sector-sensitive business with a cyclical risk profile, meaning its results can be affected by broader economic conditions. Management is labeled stable, but the thesis is still insufficiently established because there is not enough recent financial history to assess its direction.
The evidence does not provide a valuation level or clear market expectations, so it is not possible to judge whether ALMR is cheap, fair, or expensive versus peers. Fragility is labeled low, but that does not resolve the expectations gap.
Near-term, the August earnings beat is a positive sign, while the reported miss risk is low; however, the evidence also notes that industry peers have missed lately. Over the multi-year view, the fundamental path is uncertain, and the risk label recently moved from moderate to elevated.
A weakening jobs trend could increase recession concerns and weigh on cyclical names, while continued earnings strength and higher guidance from VRTX, REGN, and MRNA could sustain a Healthcare sector tailwind. Misses or lower guidance from those companies could weaken that support; the evidence does not specify ALMR-specific operating triggers.
The 1-3 year read remains uncertain: a recent earnings beat and sector support are constructive, but elevated risk and limited financial history make the long-term thesis hard to establish. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| New product launches enhance its competitive position in the market. |
| Intact |
| no successful product launches in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of at least 70% | A primary condition in Alamar Biosciences, Inc.'s published investment case. The stated target is >=70% YoY. | Intact | falls below 70% YoY revenue growth next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.67 → $-0.67 · observed estimates
$0.17B → $0.17B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-08-27 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-08-28 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-08-29 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-08-30 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-08-31 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-01 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-02 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-03 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-04 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-05 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-06 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-07 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-08 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-09 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-10 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-11 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-12 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-13 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-14 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-15 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-16 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-17 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-18 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-19 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-20 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-21 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-22 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-23 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-24 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-25 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-26 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-27 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-28 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-29 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-09-30 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-01 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-02 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-03 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-04 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-05 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-06 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-07 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-08 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-09 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-10 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-11 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-12 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-13 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-14 | $-0.67 | $165,641,600 | 3 / 3 |
| 2026-10-15 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-16 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-17 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-18 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-19 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-20 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-21 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-22 | $-0.59 | $165,709,518 | 3 / 3 |
| 2026-10-23 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-24 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-25 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-26 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-27 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-28 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-29 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-30 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-10-31 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-11-01 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-11-02 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-11-03 | $-0.59 | $165,709,518 | 3 / 4 |
| 2026-11-04 | $-0.67 | $166,069,518 | 3 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.